PD 166866

Drug Profile

PD 166866

Latest Information Update: 04 Feb 2002

Price : $50

At a glance

  • Originator Pfizer
  • Class Organic chemicals; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis; Cancer; Coronary artery restenosis; Transplant rejection

Most Recent Events

  • 04 Feb 2002 No-Development-Reported for Atherosclerosis in USA (Unknown route)
  • 04 Feb 2002 No-Development-Reported for Cancer in USA (Unknown route)
  • 04 Feb 2002 No-Development-Reported for Coronary artery restenosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top